Cubist Systematic Strategies’s Bristol-Myers Squibb BMY Stock Holding History

Cubist Systematic Strategies’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$442K	Hold	9,800	–	–	﹤0.01%	2334
2025 Q2	$454K	Sell	9,800 -59,500	-86%	-$2.92M	﹤0.01%	2285
2025 Q1	$4.23M	Sell	69,300 -353,000	-84%	-$20.6M	0.03%	984
2024 Q4	$23.9M	Sell	422,300 -19,600	-4%	-$1.1M	0.15%	147
2024 Q3	$22.9M	Buy	441,900 +331,800	+301%	+$15.6M	0.14%	151
2024 Q2	$4.57M	Buy	110,100 +45,400	+70%	+$2.03M	0.03%	834
2024 Q1	$3.51M	Sell	64,700 -31,200	-33%	-$1.59M	0.02%	1214
2023 Q4	$4.92M	Buy	95,900 +6,200	+7%	+$325K	0.03%	886
2023 Q3	$5.21M	Buy	89,700 +16,300	+22%	+$999K	0.04%	730
2023 Q2	$4.69M	Sell	73,400 -34,900	-32%	-$2.34M	0.03%	882
2023 Q1	$7.51M	Sell	108,300 -25,900	-19%	-$1.83M	0.05%	629
2022 Q4	$9.66M	Buy	134,200 +15,100	+13%	+$1.14M	0.06%	504
2022 Q3	$8.47M	Sell	119,100 -11,300	-9%	-$820K	0.05%	602
2022 Q2	$10M	Buy	+130,400	New	+$9.93M	0.06%	441

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's BMY Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Bristol-Myers Squibb (BMY) in Q3 2025: 377,758 shares worth $17M. The stake represents 0.08% of the portfolio and ranks #329 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in BMY as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in BMY in Q2 2014 and has held it in 42 quarters since. The position peaked at $50.7M in Q2 2023. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.

Cubist Systematic Strategies held 377,758 shares of Bristol-Myers Squibb worth $17M as of Q3 2025.
Bristol-Myers Squibb was a new Cubist Systematic Strategies position in Q3 2025.
Bristol-Myers Squibb made up 0.08% of Cubist Systematic Strategies's portfolio in Q3 2025, its #329 holding.
Cubist Systematic Strategies first reported a position in Bristol-Myers Squibb in Q2 2014 and has held it in 42 quarters since.
Cubist Systematic Strategies's Bristol-Myers Squibb position peaked at $50.7M in Q2 2023.
2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.